Neumora Therapeutics Inc.... (NMRA)
Company Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.
The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.
In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease.
The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| IPO Date | Sep 15, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Jason G. Duncan J.D. |
Contact Details
Address: 490 Arsenal Way Watertown, Delaware United States | |
| Website | https://www.neumoratx.com |
Stock Details
| Ticker Symbol | NMRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001885522 |
| CUSIP Number | 640979100 |
| ISIN Number | US6409791000 |
| Employer ID | 84-4367680 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason G. Duncan J.D. | Chief Legal Officer |
| Michael Lee Milligan | Chief Financial Officer & Principal Accounting Officer |
| Amy Sullivan | Chief Human Resources Officer |
| Dr. Daljit Singh Aurora Pharm.D. | Chief Operationg and development officer |
| Dr. Joshua Pinto Ph.D. | President |
| Dr. Maryjo Chamberlain-Tharp Ph.D. | Chief Business Officer |
| Dr. Nicholas Brandon Ph.D. | Chief Scientific Officer |
| Dr. Rajesh Manchanda Ph.D. | Chief Technical Operations Officer |
| Dr. Robert Lenz M.D., Ph.D. | Head of Research & Development |
| Lori Houle | Chief Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |
| Feb 18, 2025 | 4 | Filing |